Our Steps to Translating Visions into Realities

Global Leader in Genome-based Personalized Medicine

Leading Innovative Genomic Biotechnology

Our Work Does Not End Genomics, Promising Impact for Our Communities

Theragen is a comprehensive pharmaceutical and biotechnology group
Providing outstanding genetic analysis services and progressing personalized new drug development
Bio Medical Science &
Technology Division
Read More
Genome Analysis, NGS
Customized Diagnostic Solutions
Medical Big Data
Pharmaceutical DivisionRead More
Production & supply of medicines
Orphan Drug Development
Manufacturing & distributing IMD

Holding of core competence for precision medicine era The paradigm of future medicine in the fourth industrial revolution era is shifting with personalized “precision medicine” at the center. Theragen Etex receives more attention because it has both gene analysis ability and personalized drug development capability, which are core technologies for “precision medicine.”

The world’s highest level of genome analysis technology Theragen Etex has made excellent achievements using innovative technologies such as the creation of the world’s first female/tiger/minke whale genome maps and completion of the first domestic human genome map, holding the largest domestic genome analysis performance, and first commercialization of individual genome analysis service in Asia. The company is now poised to benefit from the new growth engine.

International GMP certified facilities, stable manufacturing and supply of medicines Pharmaceutical Division increased production facilities, acquired GMP certification from international consultative group, Pharmaceutical Inspection Cooperation/Scheme (PIC/S), and now stably manufactures and supplies medicines with its distribution affiliated companies. It also actively conducts research for securing a new drug pipeline such as incrementally modified drugs (IMD) or orphan drugs.

Carcinogenic gene analysis and development of novel anticancer drug With the cooperation of the world’s best research institutes and medical staff, we analyze variations in carcinogenic genes such as stomach cancer, liver cancer, head and neck cancers, and breast cancer and disease mechanisms. Vactosertib, a novel anticancer drug that we are developing, is under clinical trial in Korea and the US.

About Us Group companies make efforts to achieve a healthier and happier tomorrow.

News

2019
11Nov Medpacto, confirmation of efficacy in the clinical study on “Vactosertib” colon cancer & lung cancer

Medpacto, which is a subsidiary of TheragenEtex, officially reported the initial results of Clinical Test 1b∙2a of Vactosertib (TEW-7197). While attending the “Society for Immunotherapy of Cancer (SITC) 2019” which wa...

22Oct TheragenEtex conducts ‘genetic research on diseases after renal transplantation’ organized by the Kyung Hee University Hospital at Gangdong

TheragenEtex Bio Institute, together with the Kyung Hee University Hospital at Gangdong, conducted research in order to discover and confirm genetic markers for the prediction of chronic diseases that can occur after ren...

14Oct TheragenEtex, publication of thesis on the “age distributions of facial metrics in Koreans by age”

TheragenEtex Bio Institute published the results of a study titled, “The age distribution of facial metrics in two large Korean populations” in “Scientific Reports,” a sister journal of “Nature.” The results of this r...

01Oct TheragenEtex, publication of thesis on “relationship between gastric microbiota and gastric cancer”

TheragenEtex Bio Institute published the results of a study titled, “Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study,” which was conducted together wi...

07Aug 'Genetic testing will lead to new businesses'

Regulations hamper industry's bid to expand home test  By Nam Hyun-woo   SUWON, Gyeonggi Province ― Six years ago, actress Angelina Jolie revealed that she had a preventive double mastectomy, after genetic tes...

18Jul MedPacto Passes Technology Assessment, the Next Goal Is Listing on KOSDAQ within This Year

MedPacto, a subsidiary of TheragenEtex, has passed the technology assessment required for listing on KOSDAQ and is promoting special listing for technology.   In recently conducted technology assessment, MedPacto r...

CONTACT US

Bio Institute Division: 1522-2375
Pharmaceutical Division: 02-3463-7111
Bio Institute Division: AICT Bldg., A, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16229
Pharmaceutical Division: Daegwan Bldg., 190 Gangnam-daero, Seocho-gu, Seoul
Bio Institute Division: 031-888-9440
Pharmaceutical Division: 02-3463-8111
Bio Institute Division: bio@theragenetex.com
Pharmaceutical Division: etex@etexpharm.com